



## International Journal of PharmTech Research

CODEN (USA): IJPRIF, ISSN: 0974-4304 Vol.9, No.2, pp 182-192, 2016

# Formulation Development and Evaluation of Cimetidine Floating Microspheres

Arifa Begum. SK<sup>1,2</sup>\*, Basava Raju. D<sup>3</sup>

<sup>1</sup>Vijaya Institute of Pharmaceutical Sciences for Women, Vijayawada, Andhra Pradesh, India.
<sup>2</sup>Jawaharlal Nehru Technological University, Kukatpally, Hyderabad-500072, Telangana, India.
<sup>2</sup>Shri Vishnu College of Pharmacy, Bhimavaram, Andhra Pradesh, India.

**Abstract:** The present study was aimed to prepare Cimetidine floating microspheres by Ionotropic gelation technique with different drug to carrier ratio. All formulations of Cimetidine were characterized for particle size, scanning electron microscopy, FT-IR study, DSC, percentage yield, drug entrapment, stability studies and found to be within the limits. Among all the formulations, F13 was selected as optimized formulation based on the physicochemical and release studies. In the *in vitro* release study of formulation F13 showed 96.10% after 12 h in a controlled manner, which is essential for anti ulcer therapy. The innovator Cimetine conventional tablet showed the drug release of 96.15% within 1 h. The drug release of F13 formulation followed zero order and Higuchi kinetics indicating diffusion controlled drug release.

Key words: Cimetidine, chitosan, gum kondagogu, floating microspheres.

### Introduction:

The term microsphere is defined as a spherical particle with size varying with diameters in the micrometer range (typically 1  $\mu$ m to 1000  $\mu$ m), containing a core substance. The microspheres are characteristically free flowing powders consisting of proteins or synthetic polymers, which are biodegradable in nature and ideally having a particle size less than 200  $\mu$ m<sup>1</sup>.

As the system floats over gastric contents, the drug is released slowly at desired rate resulting in increased gastric retention with reduced fluctuations in plasma drug concentration<sup>2</sup>. Floating microspheres have emerged as an efficient means of enhancing the bioavailability and controlled delivery of many drugs the increasing sophistication of delivery technology will ensure the development of increasing number of gastro-retentive drug delivery systems to optimize the delivery of molecules that exhibit absorption window, low bioavailability and extensive first pass metabolism<sup>3,4</sup>.

Gastric emptying of dosage forms is an extremely variable process and ability to prolong and control the emptying time is a valuable asset for dosage forms, which reside in the stomach for a longer period of time than conventional dosage forms. Floating drug delivery system (FDDS) promises to be a potential approach for gastric retention. Floating microspheres have emerged as an efficient means of enhancing the bioavailability and controlled delivery of many drugs the increasing sophistication of delivery technology will ensure the development of increasing number of gastro-retentive drug delivery systems to optimize the delivery of molecules that exhibit absorption window, low bioavailability and extensive first pass metabolism<sup>5</sup>.

Peptic ulcer disease, also known as a peptic ulcer or stomach ulcer, is a break in the lining of the stomach, first part of the small intestine, or occasionally the lower esophagus. Common causes include the bacteria, *Helicobacter pylori* and non-steroidal anti-inflammatory drugs<sup>6</sup>.

Cimetidine is histamine H<sub>2</sub>-receptor antagonists, which is used to reduce the risk of stomach ulcers in patients treated with non-steroidal anti-inflammatory drugs, which has less bioavailability (60%) and lesser half life of 2 h<sup>7</sup>. The aim of present work is to design and in vitro evaluation of floating microspheres of Cimetidine to enhance its bioavailability and prolonged residence time in stomach.

#### **Materials and Methods:**

#### Materials:

Cimetidine pure drug was generous gift from Aurobindo Pharma Limited, Hyderabad, India. Sodium alginate was obtained from Pruthvi Chemicals, Mumbai. HPMC K 4 M & HPMC K 15 M was obtained from Rubicon labs, Mumbai. Xanthan gum, Guar gum, Kondagogu gum and sodium CMC were gifted from MSN Labs Ltd., Hyderabad. All other chemicals used were of analytical grade.

#### Formulation of Cimetidine Floating microspheres – Formulation design:

Cimetidine floating microspheres were prepared using polymers sodium alginate, Calcium chloride, HPMC K4M, HPMCK15M, Xanthan gum, Gum kondagogu and sodium bicarbonate by Ionic gelation method.

Formulation code	Cimetidine (g)	Sodium alginate	HPMC K4M (mg)	Sodium bi carbonate (mg)	Calcium chloride	Xanthan Gum	Guar Gum
F1	2	1%	50	25	1%	1%	0.75%
F 2	2	1.2%	75	50	1%	1.2%	0.75%
F 3	2	1.4 %	100	75	1%	1.4%	0.75%
F4	2	1.6%	150	100	1%	1.6%	0.75%
F5	2	1.8 %	175	125	1%	1.8%	0.75%
C6	2	2.%	200	150	1%	2%	0.75%
F7	2	2.2%	200	175	1%	2.2%	0.75%
Formulation code	Cimetidine (g)	Sodium alginate	HPMC K15M (mg)	Sodium bi carbonate (mg)	Calcium chloride	Xanthan Gum	Gum Kondagogu
<b>Formulation</b> code F8	Cimetidine (g) 2	Sodium alginate	HPMC K15M (mg)	Sodium bi carbonate (mg) 25	Calcium chloride	Xanthan Gum 1%	Gum Kondagogu 0.75%
Formulation code F8 F9	Cimetidine (g) 2 2	Sodium alginate 1% 1. 2%	HPMC K15M         (mg)           150         200	Sodium bi carbonate (mg) 25 50	Calcium chloride 1% 1%	Xanthan Gum 1% 1.2%	<b>Gum</b> <b>Kondagogu</b> 0.75% 0.75%
Formulation code F8 F9 F10	Cimetidine (g) 2 2 2 2	<b>Sodium</b> <b>alginate</b> 1% 1. 2% 1.4%	HPMC K15M         (mg)           150         200           250         250	Sodium bi carbonate (mg) 25 50 75	Calcium chloride 1% 1% 1%	Xanthan Gum 1% 1.2% 1.4%	Gum Kondagogu 0.75% 0.75% 0.75%
Formulation codeF8F9F10F11	Cimetidine (g) 2 2 2 2 2 2	Sodium alginate           1%           1.2%           1.4%           1.6%	HPMC K15M         (mg)           150         200           250         300	Sodium bi carbonate (mg) 25 50 75 100	Calcium chloride           1%           1%           1%           1%	Xanthan Gum 1% 1.2% 1.4% 1.6%	Gum Kondagogu 0.75% 0.75% 0.75% 0.75%
Formulation code           F8           F9           F10           F11           F12	Cimetidine (g) 2 2 2 2 2 2 2 2	Sodium alginate           1%           1.2%           1.4%           1.6%           1.8%	HPMC K15M         (mg)           150         200           250         300           350	Sodium bi           carbonate           (mg)           25           50           75           100           125	Calcium chloride           1%           1%           1%           1%           1%	Xanthan Gum 1% 1.2% 1.4% 1.6% 1.8%	Gum Kondagogu 0.75% 0.75% 0.75% 0.75% 0.75%
Formulation code           F8           F9           F10           F11           F12           F13	Cimetidine (g) 2 2 2 2 2 2 2 2 2 2	Sodium alginate           1%           1.2%           1.4%           1.6%           1.8%           2%	HPMC K15M         (mg)           150         200           250         300           350         400	Sodium bi           carbonate           (mg)           25           50           75           100           125           150	Calcium chloride           1%           1%           1%           1%           1%           1%           1%	Xanthan Gum 1% 1.2% 1.4% 1.6% 1.8% 2%	Gum Kondagogu 0.75% 0.75% 0.75% 0.75% 0.75% 0.75%

**Table 1: Formulation trials of Cimetidine Floating microspheres:** 

#### **Procedure:**

Floating microspheres of Cimetidine were prepared by ionic gelation technique using different proportion of polymers as shown in table 1. A solution of sodium alginate solution is prepared weighed quantity of drug and HPMC K4 or HPMC K15 was triturated to form fine powder and then added to above solution. Sodium bicarbonate, a gas forming agent was added to this mixture. Resultant solution was extruded drop wise with the help of syringe and needle into 100ml aqueous calcium chloride solution and stirred at 100 rpm. After stirring for 10 minutes the obtained microspheres were washed with water and dried at 60 degrees -2 hours in a hot air oven and stored in dessicater<sup>8</sup>.

#### **Evaluation of Cimetidine microspheres:**

#### Particle size:

The 100 microspheres were evaluated with respect to their size and shape using optical microscope fitted with an ocular micrometer and a stage micrometer. The particle diameters of more than 100 microspheres were measured randomly by optical microscope<sup>9</sup>.

#### Angle of repose:

Angle of repose ( $\theta$ ) of microspheres measures the resistance to particles flow, and is calculated according to fixed funnel standing cone method. Where ( $\theta$ ) is angle of repose, h/r is surface area of the free standing height of the microspheres heap that is formed on a graph paper after making the microspheres flow from glass funnel.

 $\theta = \tan^{-1}(h/r)$ 

Bulk density: Volume of the microspheres in the measuring cylinder was noted as bulk density.

Bulk density = Weight of powder Bulk volume of powder

Tapped density: Change in the microspheres volume was observed in mechanical tapping apparatus.

Tapped density = Weight of microspheres Tapped volume of microspheres

#### **Compressibility index:**

Also called as Carr's index and is computed according to the following equation.

#### Hausner's ratio:

Hausner's ratio of microspheres is determined by comparing the tapped density to the fluff density using the equation<sup>10</sup>.

Hausner's ratio = Tapped density Bulk density

#### Swelling index:

Swelling index was determined by measuring the extent of swelling of microspheres in the given medium. Exactly weighed amount of microspheres were allowed to swell in given medium. The excess surface adhered liquid drops were removed by blotting and the swollen microspheres were weighed by using microbalance. The hydro gel microspheres then dried in an oven at 60 degrees for 5 h until there was no change in the dried mass of sample. The swelling index of the microsphere was calculated by using the formula<sup>11</sup>.

Swelling index= (Mass of swollen microspheres - Mass of dry microspheres/mass of dried microspheres) X 100.

#### Drug entrapment efficiency and % yield:

In order to determine the entrapment efficiency, 10 mg of formulated microspheres were thoroughly crushed by triturating and suspended in required quantity of methanol followed by agitation to dissolve the polymer and extract the drug. After filtration, suitable dilutions were made and drug content assayed spectrophotometrically at particular wavelength using calibration curve. Each batch should be examined for drug content in a triplicate manner<sup>12</sup>.

% Drug entrapment = Calculated drug concentration /Theoretical drug concentration x 100

% yield = [Total weight of microspheres / Total weight of drug and polymer] x 100

#### Percentage buoyancy of Cimetidine floating microspheres:

*In vitro* floating ability can be determined by calculating percentage buoyancy and performed in USP type II dissolution test apparatus by spreading the floating microspheres in 0.1N HCl containing the surfactant. The media is stirred at 100 revolutions per minute (rpm) at  $37\pm 0.5$  °C. After specific intervals of time, both the fraction of microspheres (floating and settled microspheres) is collected and buoyancy of the floating microspheres is determined by using formula<sup>13</sup>.

% Floating Microspheres = Weight of floating microspheres X 100 Initial weight of floating microspheres

#### In vitro drug release studies:

In vitro drug release studies for developed Cimetidine microspheres were carried out by using dissolution apparatus II paddle type (Electrolab TDL-08L). The drug release profile was studied in 900 ml of 0.1 N HCl at  $37\pm0.5^{\circ}$ C temperature at 100 rpm. The amount of drug release was determined at different time intervals of 0, 1, 2, 3, 4, 6, 8, 10& 12 h by UV visible spectrophotometer (Shimadzu UV 1800) at 218 nm<sup>14</sup>.

#### Kinetic modeling of drug release:

In order to understand the mechanism and kinetics of drug release, the result of the *in vitro* dissolution study of microspheres were fitted with various kinetic equations, like zero order<sup>15</sup> (percentage release Vs. time), first order<sup>16</sup> (log percentage of drug remaining to be released Vs. time) and Higuchi's model<sup>17</sup> (Percentage drug release Vs. square root of time). Correlation coefficient (r<sup>2</sup>) values were calculated for the linear curves obtained by regression analysis of the above plots.

#### Drug excipient compatibility studies

The drug excipient compatibility studies were carried out by Fourier transmission infrared spectroscopy (FTIR) method, Differential Scanning Calorimetry (DSC) and SEM.

#### Fourier transform infrared spectroscopy (FTIR)

FTIR spectra for pure drug, physical mixture and optimized formulations were recorded using a Fourier transform Infrared spectrophotometer. The analysis was carried out in Shimadzu-IR Affinity 1 Spectrophotometer. The samples were dispersed in KBr and compressed into disc/pellet by application of pressure. The pellets were placed in the light path for recording the IR spectra. The scanning range was 400-4000 cm<sup>-1</sup> and the resolution was 1 cm<sup>-1</sup>.

#### **Differential Scanning Calorimetry (DSC)**

Differential Scanning Calorimetry studies were carried out using DSC 60, having TA60 software, Shimadzu, Japan. Samples were accurately weighed and heated in sealed aluminum pans at a rate of 10<sup>°</sup>C/min between 25<sup>°</sup>C and 350<sup>°</sup>C temperature range under nitrogen atmosphere, empty aluminum pan was used as a reference.

#### **SEM studies**

The surface and shape characteristics of pellets were determined by scanning electron microscopy (SEM) (HITACHI, S-3700N). Photographs were taken and recorded at suitable magnification.

#### **Stability studies**

The stability study of the optimized formulation was carried out under different conditions according to ICH guidelines. The optimized microspheres were stored in a stability chamber for stability studies (REMI make). Accelerated Stability studies were carried out at 40  $^{\circ}$ C / 75 % RH for the best formulations for 6 months. The microspheres were characterized for the percentage yield, entrapment efficiency & cumulative % drug released during the stability study period<sup>18</sup>.

#### **Results and Discussion:**

#### Floating microspheres:



Figure 1: Cimetidine floating microspheres

Table 2: Micromeretic properties of Cimetidine floating microspheres:

Formulation	Particle size	Bulk density	Tapped density	Angle of	Carr's	Buoyancy%
code	(μm)	g/cm <sup>3</sup>	g/cm <sup>3</sup>	repose	index	
F1	67.45±0.04	0.59	0.55	25°.93	13.56%	94.20%
F2	66.12±0.08	0.66	0.59	27°.74	14.34%	84.50%
F3	65.29±0.13	0.74	0.62	29°.67	11.34%	83.30%
F4	73.43±0.04	0.76	0.73	26°.03	14.36%	93.10%
F5	77.35±0.04	0.79	0.75	29°.74	12.12%	81.64%
F6	79.67±0.09	0.81	0.83	31°.15	15.23%	89.40%
F7	85.45±0.09	0.85	0.82	25°.54	13.95%	95.10%
F8	66.28±0.14	0.86	0.63	25°.91	11.32%	72.50%
F9	68.22±0.11	0.69	0.65	27°.70	13.03%	75.80%
F10	73.34±0.10	0.71	0.74	30°.24	12.34%	76.40%
F11	78.45±0.21	0.75	0.76	26°.91	11.90%	85.30%
F12	85.45±0.09	0.79	0.79	25°.02	13.90%	92.50%
F13	65.23±0.19	0.85	0.83	23°.54	9.34%	98.00%
F14	91.67±0.13	0.89	0.84	26°.91	13.94%	91.20%

All the formulations were evaluated for their micromeretic properties and physical parameters, found to be within the limits (**Table 2**). From all the above results F13 was found to be best formulation when compared with other formulations. The % buoyancy was also found to be more i.e. 98.00% among all the formulations.



Figure 2: In vitro buoyancy study of Cimetidine floating microspheres

#### Entrapment efficiency, Percentage yield and Swelling index:

Formulation F13 showed best percentage yield, entrapment efficiency and swelling Index of 98.50%, 96.30% and 94.10% respectively when compared with other formulations.

Table	3:	Percentage	yield,	entrapment	efficiency,	in	vitro	cumulative	%	drug	release	of	Cimetidine
micros	sph	eres.											

Formulation code	Percentage Yield	Entrapment efficiency	Swelling index
F1	78.09%	77.09%	76.76%
F2	81.12%	82.23%	79.78%
F3	83.23%	84.56%	83.34%
F4	86.87%	87.30%	85.23%
F5	89.30%	90.20%	88.34%
F6	90.30%	91.10%	89.78%
F7	96.10%	96.30%	90.12%
F8	86.42%	84.30%	82.23%
F9	81.56%	84.89%	84.34%
F10	89.76%	88.78%	88.45%
F11	92.78%	92.78%	89.89%
F12	86.36%	88.56%	90.10%
F13	98.50%	96.30%	94.10%
F14	85.30%	84.88%	87.90%

#### In vitro drug release studies:

Cimetidine microspheres were evaluated for *in vitro* drug release studies in 0.1N HCl and the results are depicted in **Table 4 & 5**. The formulation F13 showed best drug release of 96.10% within 12 h when compared with other formulations. The drug release of optimized formulation F13 was in controlled manner when compared with innovator product Cimetidine i.e. 96.15% within 1h.

Table 4: In vitro cumulative % drug release of Cimetidine floating microspheres:

Time (h)	F1	F2	F3	F4	F5	F6	F7
0	0±0	0±0	0±0	0±0	0±0	0±0	0±0
1	19.36±0.11	15.69±0.24	19.63±0.44	12.63±0.16	13.28±0.11	12.22±0.66	10.36±0.12
2	37.65±0.76	28.94±0.46	34.63±0.43	21.66±0.33	29.06±0.32	20.22±0.76	23.48±0.21
4	48.15±0.43	46.51±0.97	58.24±0.67	33.86±0.54	36.62±0.16	41.09±0.56	35.12±0.66
6	62.19±0.43	68.34±0.13	79.63±0.98	47.25±0.87	57.49±0.55	58.82±0.87	48.94±0.54
8	82.08±0.87	89.45±0.75	94.62±0.32	64.86±0.54	72.68±0.54	70.38±0.21	56.84±0.78
10	94.63±0.54	96.37±0.23	92.63±0.98	83.06±0.23	86.95±0.23	82.54±0.76	72.65±0.12
12	91.28±0.66	93.61±0.88	90.15±0.88	93.01±0.32	93.64±0.24	91.69±0.12	86.51±0.16



Figure 3: In vitro cumulative % drug release of Cimetidine floating microspheres

<b>T I I P I</b>	<b>r</b> •,	1 4 •	n /			e	<b>C</b> <sup>1</sup> <b>1 1 1</b>	<b>A</b>	•	1
Table 5. 1	10 1111100	oumulativa	U/~	drug	ralaaca	<b>nt</b>	( 'imotidino	thooting	microgi	nhorog
$\mathbf{I}$ a DIC $\mathcal{I}$		CUMULALINE	/0	ui uz	I CICASC	VI.	CHIEUUHE	поания	IIIICI USI	DICICS

Time	F8	F9	F10	F11	F12	F13	F14	Innovator
(h)								(Cimetin
								200mg)
0	0±0	$0\pm0$	0±0	0±0	0±0	0±0	0±0	0±0
1	8.68±0.87	$14.42 \pm 0.43$	9.25±0.65	11.29±0.65	10.31±0.55	15.62±0.43	8.66±0.15	96.15±0.16
2	19.63±0.32	25.97±0.44	17.11±0.54	20.88±0.65	22.77±0.54	22.14±0.45	12.94±0.22	
4	34.18±0.54	36.32±0.76	22.86±0.44	35.53±0.54	37.62±0.55	36.63±0.32	26.66±0.56	
6	48.65±0.43	47.37±0.43	40.27±0.87	45.92±0.54	50.65±0.45	51.33±0.65	44.17±0.65	
8	59.06±0.24	68.05±0.15	59.31±0.11	60.62±0.75	63.99±0.11	70.74±0.55	59.83±0.44	
10	63.81±0.76	76.84±0.98	75.33±0.65	76.93±0.66	75.22±0.65	84.27±0.45	76.66±0.98	
12	78.25±0.87	90.42±0.99	86.52±0.65	91.87±0.22	86.41±0.32	96.10±0.45	85.38±0.54	



Figure 4: In vitro cumulative % drug release of Cimetidine floating microspheres

#### **Release order kinetics:**

#### Table 6: Release order kinetics of optimized formulation of floating microspheres

Formula Code	Zero Order		First Order		Higuchi		Korsmeyer		
	$\mathbf{R}^2$	K	$\mathbf{R}^2$	K	$\mathbf{R}^2$	K	$\mathbf{R}^2$	Ν	
F13	0.994	7.942	0.815	0.116	0.946	28.76	0.987	1.148	

The *in vitro* release profiles from optimized formulations were applied on various kinetic models. The best fit with the highest correlation coefficient was observed in zero order and Higuchi model, indicating diffusion controlled principle. Further the n value obtained from the Korsmeyer plots i.e. 1.148 suggest that the drug release from microspheres was anomalous Non fickian diffusion.



#### Drug excipient compatibility studies:

Figure 5: FT-IR spectrum of pure drug Cimetidine



Figure 6: FT-IR spectrum of Gum Kondagogu



Figure 7: FT-IR spectrum of physical mixture (Cimetidine+HPMC K15M+Gum Kondagogu)



Figure 8: FT-IR spectrum of Cimetidine optimized formulation F13

Drug polymer interaction was checked by comparing the IR spectra of the physical mixture (Figure 7) of drug with the excipients used with the IR spectrum of pure drug (Figure 5) and optimized formulation (F13) (Figure 8) and results found that there were no possible interaction between drug and polymer (Figure 6).

#### **DSC Studies:**



#### Figure 9: DSC thermogram of Cimetidine pure drug (A) and optimized formulatin F13 (B)

DSC was used to detect interaction between Cimetidine and excipients. The thermogram of Cimetidine (**Figure 9**) exhibited a sharp endotherm melting point at 141  $^{0}$ C. The thermogram of microsphere loaded with Cimetidine exhibited a sharp endotherm melting point at 142  $^{0}$ C (**Figure 9**). There is no considerable change observed in melting endotherm of drug in optimized formulation (F13). It indicates that there is no interaction between drug & excipients used in the formulation.

#### **Scanning Electron Microscopy:**

#### Cimetidine floating optimized microspheres F13

The external and internal morphology of controlled release microspheres were studied by Scanning Electron Microscopy.

#### Floating microspheres:



Figure 10: Scanning electron micrographs of floating microspheres F13



Figure 11: Scanning electron micrographs of floating microspheres F13



Figure 12: Scanning electron micrographs of floating microspheres F13

The SEM of optimized floating microspheres shows a hollow spherical structure with a rough surface morphology. Some of microsphere showed dented surface structure but they showed good floating ability on medium indicated intact surface (**Figure 10-12**). The shell of microspheres also showed some porous structure it may be due to release of carbon dioxide.

#### **Stability studies:**

Optimized formulation (F13) was selected for stability studies on the basis of high cumulative % drug release. Stability studies were conducted by performing Percentage yield, % Entrapment efficiency and *in-vitro* drug release profile for 6 months according to ICH guidelines. From these results it was concluded that, optimized formulation is stable and retained their original properties with minor differences.

#### **Conclusion:**

From the above data, it could be concluded that Cimetidine floating microspheres exhibited prolonged and controlled release effect compared to Innovator product. All the microspheres were characterized for particle size, scanning electron microscopy, FT-IR study, DSC, percentage yield, drug entrapment, stability studies and found to be within the limits. Among all the formulations F13 were selected as optimized formulations for floating microspheres based on the physic chemical and release studies. In the *in vitro* release study of formulation F13 showed 96.10% respectively after 12 h in a controlled manner, which is essential for disease like peptic ulcer. The innovator Cimetine conventional tablet shows the drug release of 96.15% within 1 h.

#### **References:**

- 1. Chaudhari A, Jadhav KR and Kadam VJ., Microspheres as a nasal drug delivery system, International Journal of Drug Discovery, 2010, 5(1), 8-17.
- 2. Arora S, Ali J, Ahuja A, Khar R K, Baboota S., Floating drug delivery: review, AAPS Pharm SciTech, 2005, 6(3), 372-390.
- 3. Tanwar Y.S., Floating Microspheres: Development, Characterization and Applications. Pharmainfo.net, 2006, 4(3), 213-218.
- 4. Gattani Y. S, Kawtikwar P. S, Sakarkar D. M., Formulation and evaluation of Gastro retentive Multiparticulate Drug delivery system of Aceclofenac, Int J ChemTech Res, 2009, 1(1), 1-10.
- 5. Singh Bandana, Kanoujia Jovita, Pandey Manisha & Saraf Shubhini A, Formulation and Evaluation of Floating Microspheres of Famotidine, Int.J. PharmTech Res, 2010, 2(2), 1416-20.
- 6. Najm WI. "Peptic ulcer disease." Primary care, 2011, 38 (3), 383–94.
- 7. Fit KE, Williams PC, "Use of histamine2-antagonists for the treatment of verruca vulgaris". Ann Pharmacother, 2007, 41 (7), 1222–6.
- 8. Najmuddin M, Sachin S, Asgar A, Patel V and Khan T., Formulation and In vitro Evaluation of Floating Microspheres of Ketoprofen Prepared by Emulsion Diffusion Method, International Journal of Pharmacy and Pharmaceutical Research, 2010, (5)2,13-19.

- 9. Trivedi P, Verma A M. L, Garud N., Preparation and characterization of aceclofenac microspheres, Asian J. Pharm, 2008, 110-115.
- 10. Ashok T, Harish C, Mukesh P, Arvind D, Chatterjee D., Formulation and evaluation of floating microspheres of atenolol, Panacea J Pharmacy and Pharma Sci, 2015, 4(3), 654-679.
- 11. Rajput G, Majmudar F, Patel J, Thakor R, Rajgor NB., Stomach-specific mucoadhesive microsphere as a controlled drug delivery system, Sys Rev Pharm, 2010, 1, 36-44.
- 12. Deveswaran R, Manavalan R, Madhavan V, Bharath S., Formulation and Optimization of Ketoprofen Microspheres using Response Surface Methodology, International Journal of PharmTech Research, 2010, 2(4), 2319-2326.
- 13. Srivastava A. RidhurkarK, Wadhwa D N. Floating microspheres of cimetidine: formulation, characterization and *in vitro* evaluation, Acta Pharm, 2005, 55, 277–285.
- 14. Shanmugarathinam A, Vidhyeswari D, Puratchikody A., Formulation characterization and in-vitro evaluation of acrylic polymer loaded aceclofenac microspheres, Intl J Pharma and Bio Sc,i 2011, (2), 253-57.
- 15. Saparia B, Murthy RSR, Solanki A., Preparation and evaluation of chloroquine phosphate microspheres using cross-linked gelatin for long term drug delivery, Indian J Pharm Sci, 2002, 64, 48–52.
- 16. El-Gibaly I., Development and *in vitro* evaluation of novel floating chitosan microcapsules for oral use: Comparison with nonfloating chitosan microspheres, Int J Pharm, 2002, 249, 7–21.
- 17. Higuchi T., Mechanism of sustained-action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices, J Pharm Sci, 1963, 52, 1145–9.
- 18. Dandagi PM, Mastiholimath VS, Gadad AP, Iliger SR., Mucoadhesive microspheres of propranolol hydrochloride for nasal delivery, IJPS, 2007, 69(3), 402-407.

\*\*\*\*